Thanks @arkangel256. Agree with all of the above, but I'm more...

Thanks @arkangel256. Agree with all of the above, but I'm more optimistic about the cognitive outcome. It looks like they used quite simple cognitive measures. I'm wondering if the results would have been even more striking had they increased the size of the control group (why did they only include 25 controls?) and conducted a more detailed neuropsychological assessment (so they could examine more cognitive domains). They can measure, and to an extent, control for these other factors (e.g., depression, anxiety, medical comorbidities).

But either way, very interesting developments re: the measure of visual field assessment. We've always had an issue with PMD. Given the findings, they would have to push for a more simple measure of visual function (LOGMAR).

Given the current climate, and the significant delays that biotechs are facing when dealing with the FDA (I've heard that it's sometimes up to 6 months), this is just another reason to proceed with the EMA trial.